Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination

X. Cynthia(Washington University in St. Louis), Lisa A. Carey(University of North Carolina at Chapel Hill), Anna Weiss(University of Southern California), Kelly K. Hunt(The University of Texas MD Anderson Cancer Center), Jeremy Hoog(Washington University in St. Louis), Gary Unzeitig(Doctors Hospital of Laredo), Meenakshi Anurag(Baylor College of Medicine), Ann H. Partridge(Dana-Farber Cancer Institute), Wajeeha Razaq(University of Oklahoma Health Sciences Center), Abigail S. Caudle(The University of Texas MD Anderson Cancer Center), A. Marilyn Leitch(The University of Texas Southwestern Medical Center), Matthew J. Ellis(Guardant (United States)), Richard A. Gibbs(Baylor College of Medicine), Tina J. Hieken(Mayo Clinic), Charles M. Perou(University of North Carolina at Chapel Hill), Aranzazu Fernández-Martínez(University of North Carolina at Chapel Hill), Souzan Sanati(Washington University in St. Louis), Travis Dockter(Mayo Clinic), Eric P. Winer(University of Vermont), Mothaffar F. Rimawi(Baylor College of Medicine), Amy Tiersten(Icahn School of Medicine at Mount Sinai), Vera J. Suman(Mayo Clinic in Arizona), Yang Wang(Hubei University of Technology), Cheng Fan(University of North Carolina at Chapel Hill), Erika C. Crouch(Southwestern Medical Center), Monica Mita(Novartis (Switzerland)), Olwen Hahn(National Cancer Institute), Kiran Vij(Washington University in St. Louis), Joseph M. Guenther(St. Elizabeth Healthcare), Mark A. Watson(Washington University in St. Louis)

JAMA Oncology

January 18, 2024

Cited by 20

|The Lancet|2014|4.7k

|Clinical Cancer Research|2004|2.7k

|Breast Cancer Research|2010|2.1k

|Annals of Oncology|2016|2.1k

|New England Journal of Medicine|2013|2k

Related Papers